Prosecution Insights
Last updated: November 08, 2026

Evofem Inc.

Technology area: Biotechnology & Pharmaceuticals

2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready

Analysis

Evofem Inc. has 1 pending office action in Biotechnology & Pharmaceuticals. The matter is assigned to 1 examiner and 1 art unit, indicating a single examination path.

BAZARGANI, ARYA AHMADI is the identified busiest examiner and handles 1 pending matter. Prosecution preparation should focus on the examiner’s biotechnology analysis and the claims supported by the application.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

2
Total Pending OAs
1
Non-Final OAs
1
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

0
Overdue
0
Due this week
0
Due this month
1
Due in next 60 days
0
Due later

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

2
Hard (100%)
0
Medium (0%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
Multi-statute (no §101)2 (100%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

2
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

20 h
Manual time on pending OAs
4 h
Time saved (low, 20%)
7 h
Time saved (mid, 35%)
0.2 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
BAZARGANI, ARYA AHMADI 1 62.5% +31.3%
HELM, CARALYNNE E 1 28.9% +49.8%

Hard Cases (2)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.

App #TitleExaminerDue in
18407371 COMPOSITIONS AND METHODS FOR INHIBITING INFLAMMATION AND DISEASES USING AN ALGINIC ACID-BASED ANTIMICROBIAL COMPOUND HELM, CARALYNNE E 40d
18705917 RAPIDLY DISSOLVING VAGINAL FILM WITH CONTRACEPTIVE ACTION AND SEXUALLY TRANSMITTED INFECTION PREVENTION BAZARGANI, ARYA AHMADI —

Interview Candidates (2)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.

App #TitleExaminerDue in
18407371 COMPOSITIONS AND METHODS FOR INHIBITING INFLAMMATION AND DISEASES USING AN ALGINIC ACID-BASED ANTIMICROBIAL COMPOUND HELM, CARALYNNE E 40d
18705917 RAPIDLY DISSOLVING VAGINAL FILM WITH CONTRACEPTIVE ACTION AND SEXUALLY TRANSMITTED INFECTION PREVENTION BAZARGANI, ARYA AHMADI —

Top Art Units

Art UnitApps
1613 1
1615 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18705917 RAPIDLY DISSOLVING VAGINAL FILM WITH CONTRACEPTIVE ACTION AND SEXUALLY TRANSMITTED INFECTION PREVENTION BAZARGANI, ARYA AHMADI 1613 §103§112 Non-Final OA — Pending Apr 29, 2024
18407371 COMPOSITIONS AND METHODS FOR INHIBITING INFLAMMATION AND DISEASES USING AN ALGINIC ACID-BASED ANTIMICROBIAL COMPOUND HELM, CARALYNNE E 1615 §103§112Other Final Rejection 40d Pending Jan 08, 2024

Managing Evofem Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

How many pending USPTO office actions does Evofem Inc. have?

Evofem Inc. has 2 pending office actions as of November 2026, spread across 2 art units and 2 examiners.

Which USPTO examiner handles the most Evofem Inc. applications?

Arya Ahmadi Bazargani has the most, with 1 of Evofem Inc.'s pending office actions.

What technology area are Evofem Inc.'s patent applications in?

Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month